 |
Zevalin, as part of the Zevalin therapeutic regimen, is indicated for the treatment of patients with relapsed or refractory, low‑grade or follicular B‑cell non‑Hodgkin's lymphoma (NHL), including patients with rituximab refractory follicular NHL.
The Zevalin therapeutic regimen has been given accelerated approval for the treatment of relapsed or refractory, rituximab-naïve, low‑grade and follicular NHL based on studies that have shown durable objective overall response rates, a surrogate endpoint for progression-free survival. Studies to determine whether the Zevalin therapeutic regimen confers an effect on progression-free survival are ongoing. |
|
Please consult full prescribing information for Zevalin and Rituximab, including their respective Boxed WARNINGS.
|
